Utilizing Echocardiography to Raise Suspicion of Transthyretin Cardiac Amyloidosis (ATTR-CM).

During this presentation you will hear from an expert cardiologist and sonographer on how to recognize the signs of ATTR-CM using echocardiology, tips to enhance echo image quality and enable accurate measurement, as well as an overview of how to appropriate diagnose and manage patients with ATTR-CM.

PP-VDM-USA-1575

This is an informational presentation brought to you by Pfizer. No credits are available.

INDICATION

VYNDAQEL^® (tafamidis meglumine) and VYNDAMAX^® (tafamidis) are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions

In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL was similar to placebo.

Specific Populations​​​​​​​

Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.

Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.

Please see Full Prescribing Information including Patient Information.

• Contact:
  ASE Learning Hub